{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-25-000023","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.727727+00:00","generated_at":"2026-05-23T22:35:07.989685+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AbbVie revises FY 2025 adj. EPS guidance down $0.13 on $248M IPR&D charge","bullets":["Q1 2025 includes $248M pre-tax acquired IPR&D and milestones expense.","Q1 2025 adjusted diluted EPS guidance: $2.34-$2.38 (prior $2.47-$2.51).","Full-year 2025 adjusted diluted EPS guidance: $11.99-$12.19 (from $12.12-$12.32).","Revised guidance excludes AbbVie-Gubra GUB014295 licensing deal closed after Q1.","Company does not forecast future IPR&D milestones due to uncertainty."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-25-000023","json":"https://secwatch.observer/filing/0001551152-25-000023.json","markdown":"https://secwatch.observer/filing/0001551152-25-000023.md","text":"https://secwatch.observer/filing/0001551152-25-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000023/0001551152-25-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000023/abbv-20250403.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:35:07.989685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}